HI
PRME icon

Harbour Investments’s Prime Medicine PRME Stock Holding History

Harbour Investments’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258 Buy
+74
New +$282 ﹤0.01% 4396

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Harbour Investments's PRME Position: Q1 2026 in Review

Harbour Investments opened a new position in Prime Medicine (PRME) in Q1 2026: 74 shares worth $258. The stake represents ﹤0.01% of the portfolio and ranks #4396 among its holdings.

192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Harbour Investments held 74 shares of Prime Medicine worth $258 as of Q1 2026.
  • Prime Medicine was a new Harbour Investments position in Q1 2026.
  • Prime Medicine made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4396 holding.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.